In vitro activity and adaptation strategies of eravacycline in clinical Enterococcus faecium isolates from China

Wen, Zewen; Liu, Fangfang; Zhang, Peixing; Wei, Ying; Shi, Yiyi; Zheng, Jinxin; Li, Guiqiu; Yu, Zhijian; Xu, Zhicao; Deng, Qi; Chen, Zhong

doi:10.1038/s41429-022-00546-2

Cited by 2 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biofilm formation of parental S. aureus YUSA145 isolates was cultured in an incubator at 37°C for 24 h, and the biofilm suspension was inoculated with the control and the radezolid (1/8 × MIC) for another 24 h. After the bacterial suspension was removed, the S. aureus biofilm cells were collected and homogenized with glass beads for three rounds and centrifuged at 4°C. The total protein of the bacterial supernatant was obtained, and the protein concentration was determined using the BCA protein assay kit (Beyotime Biotechnology, Shanghai, China) ( Wen et al, 2022 ; Zhang et al, 2022 ). The 100 μg protein was pretreated for quantitative analysis by nano LC-MS/MS.…”

Section: Methodsmentioning

confidence: 99%

Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China

et al. 2023

Self Cite

View full text Add to dashboard Cite

Although the potent antibacterial ability of radezolid against Staphylococcus aureus has been widely reported worldwide, its antibacterial and anti-biofilm activity against the S. aureus clinical isolates from China remains elusive. In this study, the minimum inhibitory concentration (MIC) of radezolid was determined in S. aureus clinical isolates from China using the agar dilution method, and the relationship between radezolid susceptibility and ST distribution was also investigated. The anti-biofilm activity of radezolid against S. aureus was determined by a crystal violet assay and compared with that of linezolid and contezolid. The quantitative proteomics of S. aureus treated with radezolid was analyzed, and the genetic mutations in radezolid-induced resistant S. aureus were determined by whole-genome sequencing. The dynamic changes in transcriptional expression levels of several biofilm-related genes were analyzed by quantitative RT-PCR. Our data showed that radezolid MIC ranged from ≤0.125 to 0.5 mg/L, which was almost 1/4 × MIC of linezolid against S. aureus, indicating the greater antibacterial activity of radezolid than linezolid. The S. aureus clinical isolates with radezolid MICs of 0.5 mg/L were most widely distributed in ST239 of MRSA and ST7 of MSSA. Moreover, the more robust anti-biofilm activity of radezolid with subinhibitory concentrations (1/8 × MIC and 1/16 × MIC) was demonstrated against S. aureus when compared with that of contezolid and linezolid. Genetic mutations were found in glmS, 23S rRNA, and DUF1542 domain-containing protein in radezolid-induced resistant S. aureus selected by in vitro induction of drug exposure. Quantitative proteomic analysis of S. aureus indicated that the global expression of some biofilm-related and virulence-related proteins was downregulated. Quantitative RT-PCR further confirmed that the expressions of some downregulated biofilm-related proteins, including sdrD, carA, sraP, hlgC, sasG, spa, sspP, fnbA, and oatA, were decreased after 12 h and 24 h of exposure to radezolid. Conclusively, radezolid shows robust antibacterial and anti-biofilm activity against S. aureus clinical isolates from China when compared with contezolid and linezolid.

show abstract

Section: Methodsmentioning

confidence: 99%